IO Biotech appoints Dr. Eva Ehrnrooth as Chief Medical Officer

Oct 12, 2017

Copenhagen, Denmark – October 12, 2017: IO Biotech, a private company developing novel immuno-oncology therapies targeting immune checkpoint inhibitory targets to treat cancer, today announced the appointment of Eva Ehrnrooth, M.D., Ph.D., to the position of chief medical officer.

Other news

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

IO Biotech Announces Third Quarter Results for 2022

IO Biotech Announces Third Quarter Results for 2022